PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT.

Autor:	Baghbanian M; Department of Gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran., Halvani M; Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran., Roghani HS; Department of Gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran., Lotfi MH; Biostatistics & Epidemiology, Health Faculty, Shaheed Sadoughi University of Medical Sciences, Daneshju Blv. Yazd, Iran., Yazdi MF; Department of haematology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran., Vahedian-Ardakani HA; Department of haematology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Jazyk:	angličtina
Zdroj:	Arquivos de gastroenterologia [Arq Gastroenterol] 2016 Jul-Sep; Vol. 53 (3), pp. 175-9.
DOI:	10.1590/S0004-28032016000300010
Abstrakt:	Background: Occult hepatitis B infection is characterized by negative hepatitis B surface antigen (HBsAg) and also detectable hepatitis B virus (HBV) -DNA, with or without hepatitis B core antibody (anti-HBc). HBV reactivation in individuals under immunosuppressive therapy is critical, occurring in occult HBV. Objective: In this study, we aimed to determine the prevalence of occult HBV infection among hepatitis B surface antigen negative in cancer patients before receiving chemotherapy. Methods: Sera from 204 cancer patients who were negative for HBsAg, were tested for anti-HBc antibodies. The samples that were negative for HBsAg but positive for anti-HBc also examined for HBV-DNA by polymerase chain reaction (PCR). Results: Of the 204 HBsAg negative blood samples, 11 (5.4%) samples were positive for anti-HBc antibodies. HBV-DNA was detected in 9/11 (81%) of anti-HBc positive samples. Occult HBV infection in hematological cancers was more than solid cancers, 4.8% and 4.3% respectively. There was no significant difference in HBc antibody positivity based on vaccination, previous blood transfusions, history of familial hepatitis or biochemical parameters (ALT, AST, total and direct bilirubin levels) (P>0.05). Conclusion: Screening of occult HBV infection by HBsAg, HBV DNA and anti HB core antibody should be suggested as a routine investigation in cancer patients before receiving chemotherapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu